Vitamin d and Splenic infarction - a phase IV clinical study of FDA data

Summary:

Splenic infarction is reported as a side effect among people who take Vitamin d (ergocalciferol), especially for people who are male, 60+ old, also take Ondansetron, and have Primary myelofibrosis.

The phase IV clinical study analyzes which people have Splenic infarction when taking Vitamin d. It is created by eHealthMe based on reports of 282,675 people who have side effects when taking Vitamin d from the FDA, and is updated regularly.

What is Vitamin d?

Vitamin d has active ingredients of ergocalciferol. It is often used in low vitamin d. eHealthMe is studying from 294,094 Vitamin d users. Check the latest studies of Vitamin d.

What is Splenic infarction?

Splenic infarction (tissue damage of spleen) is found to be associated with 289 drugs and 529 conditions by eHealthMe. Check the latest studies of Splenic infarction.

On Jul, 07, 2026

282,675 people reported to have side effects when taking Vitamin d.
Among them, 18 people (0.01%) have Splenic infarction.

Could Vitamin d cause Splenic infarction?

Among these 18 people:

What is the gender of people who have Splenic infarction when taking Vitamin d? *

female: 47.06 %
male: 52.94 %

What is the age of people who have Splenic infarction when taking Vitamin d? *

What are other drugs people take besides Vitamin d? *

What are other side effects people have besides Splenic infarction? *

Thrombocytopenia (decrease of platelets in blood): 6 people, 33.33%
Sepsis (a severe blood infection that can lead to organ failure and death): 5 people, 27.78%
Head Injury: 5 people, 27.78%
Splenomegaly (enlargement of spleen): 5 people, 27.78%
Dehydration (dryness resulting from the removal of water): 4 people, 22.22%
Pleural Effusion (water on the lungs): 4 people, 22.22%
Cardiac Arrest: 4 people, 22.22%
Calculus Bladder (bladder stone): 4 people, 22.22%
Fall: 4 people, 22.22%
Primary Myelofibrosis (primary disorder of the bone marrow): 4 people, 22.22%

What are the existing conditions these people have? *

Primary Myelofibrosis (primary disorder of the bone marrow): 5 people, 27.78%
Urinary Tract Infection: 4 people, 22.22%
Pain: 3 people, 16.67%
Iron Binding Capacity Total Abnormal: 3 people, 16.67%
Chronic Lymphocytic Leukaemia (cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell)): 3 people, 16.67%
Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 2 people, 11.11%
Schizophrenia (a mental disorder characterized by a breakdown of thought processes): 1 person, 5.56%
Pulmonary Embolism (blockage of the main artery of the lung): 1 person, 5.56%
Neuroblastoma (a cancer that forms in your nerve tissue): 1 person, 5.56%
Nausea (feeling of having an urge to vomit): 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Vitamin d and have Splenic infarction?

- Check whether Splenic infarction is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Vitamin d:

Vitamin d (294,094 reports)

Browse all side effects of Vitamin d:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Splenic infarction:

Splenic infarction (289 drugs)

Browse all the conditions that are associated with Splenic infarction:

Splenic infarction (529 conditions)

Related publications that referenced our studies

Kapoor S, "Influence of Vitamin D Consumption and Levels on the Development of Psychiatric Disorders", Lee, Y. J., & Park, K. (2018). Secondary Raynaud’s Phenomenon and Skin Necrosis of Toes in the Paraplegic Patient with Hypertension.?Drug safety-case reports,?5(1), 7., 2014 Aug .
Misgar, R. A., Bhat, J. A., Wani, A. I., & Bashir, M. I., "Sitagliptin induced splenic infarcts", Clinical Diabetology, 2014 Jan .
Kapoor S, "Influence of Vitamin D Consumption and Levels on the Development of Psychiatric Disorders", Lee, Y. J., & Park, K. (2018). Secondary Raynaud’s Phenomenon and Skin Necrosis of Toes in the Paraplegic Patient with Hypertension.?Drug safety-case reports,?5(1), 7., 2014 Aug .
Misgar, R. A., Bhat, J. A., Wani, A. I., & Bashir, M. I., "Sitagliptin induced splenic infarcts", Clinical Diabetology, 2014 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on ergocalciferol (the active ingredients of Vitamin d) and Vitamin d (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.